Overview
TB-500 is a synthetic peptide fragment derived from thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein. It represents the N-terminal active heptapeptide sequence Ac-LKKTETQ, which is responsible for actin-binding and cell-migration properties.
Quick Start Highlights
– Reconstitution: Add 3.0 mL bacteriostatic water to create ~3.33 mg/mL concentration
– Daily dosage range: 500–1000 mcg once daily via subcutaneous injection
– Measurement convenience: At 3.33 mg/mL, 1 unit on U-100 insulin syringe ≈ 33.3 mcg
– Storage (lyophilized): −20 °C (−4 °F) in dry, dark conditions
– Storage (reconstituted): 2–8 °C (35.6–46.4 °F); do not freeze; use within 28 days
Dosing Protocol
Gradual Titration Schedule (8-12 week cycle)
| Phase | Daily Dose | Insulin Syringe Units |
|---|---|---|
| Weeks 1–2 | 500 mcg | 15 units (0.15 mL) |
| Weeks 3–4 | 600 mcg | 18 units (0.18 mL) |
| Weeks 5–8 | 750 mcg | 23 units (0.23 mL) |
| Weeks 9–12 | 1000 mcg | 30 units (0.30 mL) |
Frequency: Once daily subcutaneous injection
Cycle length: 8–12 weeks; optional extension to 16 weeks
Timing: Any consistent daily time; rotate injection sites
Reconstitution Instructions
1. Draw 3.0 mL bacteriostatic water using sterile syringe
2. Inject slowly down vial wall to avoid foaming
3. Gently swirl or roll until fully dissolved (do not shake)
4. Label with date and concentration
5. Refrigerate at 2–8 °C, protected from light
Supplies Needed (8-16 week protocol)
TB-500 Vials (10 mg each):
– 8 weeks: ~4 vials
– 12 weeks: ~7 vials
– 16 weeks: ~10 vials
Insulin Syringes (U-100):
– 8 weeks: 56 syringes
– 12 weeks: 84 syringes
– 16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles):
– 8 weeks (4 vials): 2 bottles
– 12 weeks (7 vials): 3 bottles
– 16 weeks (10 vials): 3 bottles
Alcohol Swabs:
– 8 weeks: 2 × 100-count boxes
– 12 weeks: 2 × 100-count boxes
– 16 weeks: 3 × 100-count boxes
Mechanism of Action
TB-500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation. Research in animal models demonstrates enhanced collagen deposition and reduced healing time at injury sites. Recent studies suggest TB-500 may function as a prodrug, cleaving to an active pentapeptide metabolite that drives biological activity.
Potential Benefits
– “Accelerated wound healing and tissue repair through enhanced angiogenesis” and cell migration mechanisms
– May reduce inflammation and fibrosis indirectly via thymosin pathways observed in animal models
– Generally well tolerated in veterinary studies with occasional mild injection-site reactions
Potential Side Effects
– Occasional mild injection-site reactions (redness, tenderness)
– Human safety data is limited; no large-scale clinical trials completed specifically for TB-500
– No FDA approval for human administration
Injection Technique
– Clean vial stopper and skin with alcohol; allow to air dry completely
– Pinch skinfold at injection site; insert needle at 45–90° into subcutaneous tissue
– Do not aspirate for subcutaneous injections; inject slowly and steadily
– Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy
– Wait 5–10 seconds after injection before withdrawing needle
Storage Instructions
Lyophilized:
– Store at −20 °C (−4 °F)
– Keep in dry, dark conditions
– Minimize moisture exposure
– Allow vials to reach room temperature before opening to reduce condensation
Reconstituted:
– Refrigerate at 2–8 °C (35.6–46.4 °F)
– Do not freeze (freezing denatures peptides)
– Use within 28 days with bacteriostatic water preservative
Important Notes & Lifestyle Factors
– Use new sterile insulin syringes for each injection; dispose in sharps container
– Rotate injection sites to reduce local irritation and lipohypertrophy
– Maintain adequate protein intake to support tissue repair
– Combine with appropriate physical activity; avoid overtraining during recovery
– Prioritize 7–9 hours of sleep to maximize natural recovery
– Manage stress through evidence-based practices
– Document daily dose, injection site, and observations
Regulatory Status
TB-500 is banned by WADA for athletic use and is not FDA-approved for human administration. This protocol is for research purposes only and does not constitute medical advice.
References
Sources cited include FASEB Journal, Journal of Chromatography A, WADA Scientific Research, Racing Medication & Testing Consortium, Journal of Investigative Dermatology, verified peptide storage guides, and clinical injection technique guidelines.